Study of Epratuzumab Versus Placebo in Subjects With Moderate to Severe General Systemic Lupus Erythematosus
Status:
Completed
Trial end date:
2015-05-01
Target enrollment:
Participant gender:
Summary
The primary objective of the study is to confirm the clinical efficacy of epratuzumab in the
treatment of subjects with Systemic Lupus Erythematosus (SLE)